H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on NextCure (NXTC – Research Report) today and set a price target of $3.00.
Emily Bodnar’s rating is based on several promising developments surrounding NextCure’s LNCB74, particularly in the context of endometrial cancer treatment. The recent data from AstraZeneca’s BLUESTAR trial, which showed high overall response rates (ORR) in endometrial cancer patients, suggests a significant opportunity for LNCB74. This is especially relevant given the lack of a standard of care in second-line endometrial cancer, where typical ORR with chemotherapy is much lower.
Furthermore, NextCure’s ongoing Phase 1 trial for LNCB74 is progressing well, with no dose-limiting toxicities observed so far. The company plans to expand patient cohorts to better determine optimal dosing, which could enhance the drug’s efficacy profile. These factors, combined with the potential for LNCB74 to outperform existing treatments in other cancer models, underpin Bodnar’s optimistic Buy rating for NextCure’s stock.
According to TipRanks, Bodnar is an analyst with an average return of -5.4% and a 27.54% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as AnaptysBio, Jasper Therapeutics, and Agenus.
In another report released on March 7, Piper Sandler also maintained a Buy rating on the stock with a $3.00 price target.